<DOC>
	<DOCNO>NCT02863601</DOCNO>
	<brief_summary>The primary purpose study determine whether buprenorphine metabolite exposure ( reflect dose-adjusted plasma concentration x time curve [ AUC ] ) differs pregnancy pregnancy postpartum state.The study define pharmacokinetics buprenorphine determine good way gauge dose base objective , physiological parameter satiety . The study also determine maternal , placental fetal factor impact risk Neonatal Abstinence Syndrome ( NAS ) define neonatal exposure buprenorphine breast milk .</brief_summary>
	<brief_title>Impact Pregnancy Buprenorphine Pharmacokinetics Pharmacodynamics</brief_title>
	<detailed_description>Currently , standard care opioid-dependent pregnant woman institution methadone , however , buprenorphine ( BUP ) also use indication , FDA-approved opioid addiction although specifically pregnant woman . There increase evidence BUP may comparable efficacy methadone , may fewer severe neonatal complication especially neonatal abstinence syndrome ( NAS ) decrease severity adverse reaction . The dose BUP currently base study men non-pregnant woman ( adjusted patient 's symptomatology use Clinical Opiate Withdrawal ( COW ) score , subjective base objective physiological parameter ) limit animal data relate plasma concentration BUP degree saturation Âµ receptor brain10-13 . The study team define pharmacokinetics pharmacodynamics BUP early late pregnancy postpartum period determine contribute variation plasma concentration response also relate plasma concentration BUP major metabolite physiologic parameter use gauge amount drug mother 's plasma . It expect demonstrate high dos BUP need throughout pregnancy dose regimen adjust use patient covariates biophysical measurement addition COW score . Additionally , study team evaluate several maternal newborn variable might predictive NAS .</detailed_description>
	<mesh_term>Opioid-Related Disorders</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>Age 18 45 year Currently stable twice three time daily dose sublingual BUP Willingness participate 2 pharmacokinetic ( PK ) /pharmacodynamic ( PD ) study pregnancy 1 PK Study pregnancy ) Gestational age &lt; 19 0/7 week Singleton gestation Able give inform consent undergo study procedure Willing urine sample screen presence alcohol , barbiturate , opiate , cocaine ( metabolite ) , benzodiazepine , synthetic opioids phencyclidine Major fetal anomaly malformation HIV AIDS Comorbid dependence benzodiazepine central nervous system depressant ( include antiseizure medicationssee MOO ) Taking medication know interfere buprenorphine metabolism Active chronic suicidal homicidal ideation attempt Elevated liver enzymes ( AST , alanine aminotransferase ( ALT ) &gt; 2 time normal ) Creatinine &gt; 1.5 mg/dl Delivery institution outcome data obtain mother baby Active use heroin , cocaine non prescribe opiates Hematocrit &lt; 28</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Buprenorphine</keyword>
	<keyword>Opiate Substitution Treatment</keyword>
</DOC>